Kevin Kunzmann

Yuanyuan Zhao, MD, discusses phase 1b data for the PD-1/VEGF bispecific RC148 (ABBV-1480) plus chemotherapy in first-line NSCLC, how it is engineered differently from ivonescimab and pumitamig, and what the global phase 3 program needs to show.

Jay M. Lee, MD, discusses how NAUTIKA1 compares with ALNEO and LORIN, why full genomic profiling is now essential before starting chemoimmunotherapy, and how tumor boards will manage early-stage NSCLC in 5 years.

Jay M. Lee, MD, discusses the primary analysis of the ALK+ cohort of NAUTIKA1, what MPR status adds to risk stratification, and whether neoadjuvant alectinib is ready for patients today.

The dose-finding DeLLphi-308 trial showed promising results for a more convenient administration of tarlatamab in patients with ES-SCLC.

The phase 3 LONESTAR trial was closed early for futility after added local consolidative therapy showed no OS or PFS benefit, including in oligometastatic disease.